Pfizer Inc. and BioNTech announced yesterday that they have signed a $ 3.2 billion (€ 3.6 billion) deal with the US government to supply 105 million doses of their COVID-19 vaccine.
The installments are expected to be delivered by the end of the summer.
The deal includes a vaccine adapted to the Omicron variant, and is expected to be licensed, according to Pfizer.
Manufacturers of COVID-19 vaccines, including Pfizer, are developing vaccines targeting the Omicron variant, which dominated the spread of infections last winter, causing a massive increase in cases.
The average installment price provided in the agreement exceeds $ 30 (28.71 euros). This is an increase of more than $ 19.50 (€ 18.66) per installment, paid by the US government in its initial contract with Pfizer.
Some of the adult doses included in this contract will be in single-dose vials, which have higher mass production costs but reduce dose losses from vials already opened for use.
U.S. Food and Drug Administration advisers have proposed a change in the planning of COVID-19 boost doses this fall to combat more recent coronavirus strains.
SOURCE: AMPE
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
